While the safety profile of SPRYCEL in the elderly population was similar to that in the younger population, patients aged 65 years and older are more likely to experience fluid retention events and should be monitored closely (see section 4.8).
Kuigi SPRYCEL' i ohutusprofiil eakatel ja nooremal populatsioonil oli sarnane, esineb 65 aastastel ja vanematel patsientidel vedelikupeetust sagedamini ning neid tuleb hoolikamalt jälgida (vt lõik 4. 8).